ArticleBlood cancer discovery2021
Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy.
Article in Blood cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 71 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Biomarkers for predicting CAR-T cell therapy outcomes in B-cell acute lymphoblastic leukemia: a systematic review.Frontiers in immunology · 2025Pooled it
- Article
- Comparative clinical outcomes and single-cell profiling of CD19 CAR-T versus blinatumomab for relapsed/refractory B-ALL.Journal for immunotherapy of cancer · 2026Article
- Beyond Remission: Risk-Adapted Maintenance and Mechanism-Guided Salvage After CAR T-Cell Therapy for Multiple Myeloma.Stem cell reviews and reports · 2026Review
- Functional immune profiling translates T cell dynamics into predictive biomarkers for myeloma immunotherapy.Leukemia · 2026Article
- Multiple Myeloma Cells Resistant to T-cell Therapies Exhibit a CD45+ Immunoevasive Phenotype.Cancer immunology research · 2026Article
- Review
- Uncoupled bone remodeling drives myeloma bone disease in Vk*MYC mouse model of multiple myeloma.Bone reports · 2026Article
- Epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma: how should this regimen be positioned in current treatment algorithms?Translational cancer research · 2026Article
- Debulking Chemotherapy Can Overcome Primary Resistance to Teclistamab in Relapsed/Refractory Multiple Myeloma.Blood cancer discovery · 2026Article
- A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.Blood advances · 2026Article
- T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T cells.bioRxiv : the preprint server for biology · 2026Article
- Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.Experimental hematology & oncology · 2026Article
- Beyond exhaustion: T cell fitness for next generation of immunotherapy for hematological cancer.Frontiers in immunology · 2026Review
- Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies.Frontiers in immunology · 2026Review
- Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myeloma.bioRxiv : the preprint server for biology · 2025Article
- The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.Blood cancer journal · 2025Article
- A Phase I Clinical Study and In Vivo Findings with PT-112, a Novel Immunogenic Cell Death-Inducing Small Molecule, in Relapsed or Refractory Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Bispecific antibodies: unleashing a new era in oncology treatment.Molecular cancer · 2025Review
- T cell phenotype and clonality changes in myeloma patients with short overall survival.JCI insight · 2025Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
Abstract
BCMA-CD3-targeting bispecific antibodies (BsAb) are a recently developed immunotherapy class which shows potent tumor killing activity in multiple myeloma (MM). Here, we investigated a murine BCMA-CD3-targeting BsAb in the immunocompetent Vk*MYC and its IMiD-sensitive derivative Vk*MYC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.